La importancia de la primera línea en el cáncer de cabeza y cuello resistente o metastásico

32 / 43

Author’s conclusion:
Paclitaxel + cetuximab showed similar OS & PFS in unselected patients with R/M SCCHN as previously reported in a Phase II
trial, confirming its value in unfit patients1,2
32
• 1. Pajares Bernad I, et al. ESMO 2016 (Abstract 991P)
• 2. Hitt R, et al. Ann Oncol 2012;23:1016–22
Image courtesy of AlfredoCreates.com via the Noun Project
• *QW paclitaxel + cetuximab is an off-label treatment in R/M SCCHN
100
90
80
70
60
50
40
30
20
10
0
0 12 24 38 48 60 72
OS (%)
Time (months)
Median OS, 10 months
(95% CI 8.3–11.7)1
Efficacy1
Cetuximab +
paclitaxel*
(N=148)
ORR, % 47.3
SD, % 20.3
PD,% 32.4
Median OS, months (95% CI) 10 (8.3–11.7)
Median PFS, months (95% CI) 7 (5.9–8.1)